US 2010/0063251 A1 · COMPOSITIONS AND METHODS FOR TREATMENT OF CHRONIC FATIGUE SYNDROME AND NEURODEGENERATIVE DISEASES

Abstract

The present invention relates to use of pharmaceutical formulations of a-MSH for the treatment of chronic fatigue syndrome and neurodegenerative diseases.

Claims4

Dependent claims

Use of the peptide a-MSH for manufacturing of a medicament for treatment of chronic fatigue syndrome.

Dependencies are inferred from the claim text.

Facts

Application

12/440,979Filed 14 Sep 2006

Published

11 Mar 2010

Term ends

Not estimatedThe source records don’t support an estimate.

Classification22 codes

A61K 38/34
Derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin: melanocyte stimulating hormone [MSH], e.g. alpha- or beta-melanotropin
A61K 9/0078
Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy: for inhalation via a nebulizer…
A61P 1/04
Drugs for disorders of the alimentary tract or the digestive system: for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of…
A61P 1/08
Drugs for disorders of the alimentary tract or the digestive system: for nausea, cinetosis or vertigo; Antiemetics

Abstract

The present invention relates to use of pharmaceutical formulations of a-MSH for the treatment of chronic fatigue syndrome and neurodegenerative diseases.

Compositions and methods for treatment of chronic fatigue syndrome and neurodegenerative diseases

Life of this patent

Abstract

Claims4

Compositions and methods for treatment of chronic fatigue syndrome and neurodegenerative diseases

Life of this patent

Abstract

Claims4